TrivarX Appoints Experienced CEO to Accelerate Stabl-Im Brain Cancer Trials

Experienced CEO to Drive Clinical Milestones

TrivarX Limited (ASX:TRI) has appointed Dr Danielle Meyrick as its new CEO, effective 1 June 2026, tasking her with advancing the company's Stabl-Im platform through its critical first-in-human clinical trials and towards commercialisation. Dr Meyrick’s two decades of expertise in radiopharmaceuticals, isotope technologies, and clinical trial leadership, including senior roles at Telix Pharmaceuticals and ITM Isotopes, align closely with TrivarX’s ambitions to translate its stable isotope MRI technology into viable brain cancer diagnostics.

Her appointment follows TrivarX’s recent acquisition of the Stabl-Im intellectual property and substantial capital raises to fund clinical development, including a $4.2 million placement earlier this year, which bolstered the company’s capacity to initiate trials and regulatory engagement $4.2M raise and Stabl-Im acquisition. The company is currently in advanced negotiations with Contract Research Organisations (CROs) to support trial design and execution, aiming to complete Phase 1 safety studies within the 2026 calendar year.

Stabl-Im’s Potential to Transform Brain Cancer Imaging

The Stabl-Im platform offers a novel, non-invasive imaging method by using stable isotope labelling combined with standard MRI to visualise replicating cells within the brain. This approach could represent a breakthrough in safely monitoring brain cancers, potentially overcoming the limitations of current imaging techniques that often involve radiation or invasive procedures.

Dr Meyrick emphasised the technology’s promise to provide real-time visualisation of cellular activity, which may enable earlier detection and more precise monitoring of disease progression. This could translate into improved clinical decision-making and patient outcomes, particularly in neuro-oncology where diagnostic options remain limited.

TrivarX’s strategy to progress Stabl-Im through clinical development is supported by ongoing collaborations with the platform’s inventor, Dr Daniel Tillett, and builds on prior funding rounds that have secured over $3.5 million to scale manufacturing and prepare regulatory submissions funding for manufacturing scale-up. The company remains well funded to meet its near-term milestones.

Incentives Aligned with Clinical and Regulatory Success

Dr Meyrick’s employment package includes a base salary of $300,000 per annum, supplemented by short-term incentives contingent on achieving specific clinical milestones such as completion of a Phase 1 safety study in at least 20 subjects and FDA pre-IND submission. Long-term incentives comprise 15 million options and 25 million performance rights, with vesting tied to regulatory approvals and successful Phase 2 imaging studies.

This remuneration structure underscores TrivarX’s focus on progressing Stabl-Im through critical clinical and regulatory inflection points. The CEO’s mandate is clear: to navigate complex clinical trial design, regulatory engagement with agencies like the FDA, and position the company for eventual commercialisation.

Leadership Signals a Shift Toward Execution

Non-Executive Chairman David Trimboli highlighted Dr Meyrick’s proven ability to translate scientific innovation into clinically and commercially viable programs, a capability the company deems essential as it moves beyond early-stage development. Her appointment marks a strategic pivot for TrivarX from technology acquisition and validation to active clinical execution and market readiness.

While the company is advancing rapidly, the path ahead remains contingent on successful trial outcomes and regulatory approvals, milestones that will be closely watched by investors and industry observers alike.